Effect of Adjuvant Chemo on Elderly Patients’ Quality of Life

Article

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.

In this Medical News Minute developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses recently published research that looks at quality of life outcome measures for elderly breast cancer patients who receive adjuvant chemotherapy.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC

Chris Ryan
October 17th 2025
Article

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Local Consolidative Therapy Plus Osimertinib Yields PFS Benefit in Metastatic EGFR-Mutant NSCLC

Kristi Rosa
October 17th 2025
Article

Osimertinib and local consolidative therapy was a safe and effective strategy to extend disease control in patients with advanced EGFR-mutant NSCLC.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.

Abemaciclib Regimen Improves Survival in HR+/HER2– Early Breast Cancer

Ashling Wahner
October 17th 2025
Article

Data from monarchE showed an OS benefit with abemaciclib-based therapy that was consistent across prespecified patient subgroups.